Advertisement

Reviews in Endocrine and Metabolic Disorders

, Volume 17, Issue 3, pp 373–380 | Cite as

Flushing in (neuro)endocrinology

  • Fady Hannah-Shmouni
  • Constantine A. Stratakis
  • Christian A. Koch
Article

Abstract

Cutaneous flushing is a common presenting complaint in endocrine disorders. The pathophysiology of flushing involves changes in cutaneous blood flow triggered by multiple intrinsic factors that are either related to physiology or disease. Flushing can be divided into episodic or persistent causes. Episodic flushing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing results in a fixed facial erythema with telangiectasia and cyanosis due to slow-flowing deoxygenated blood in large cutaneous blood vessels. The differential diagnosis of cutaneous flushing in neuroendocrine disorders is limited, yet encompasses a broad spectrum of benign and malignant entities, including carcinoid syndrome, pheochromocytoma, Cushing syndrome, medullary thyroid cancer, and pancreatic neuroendocrine tumors. In this review, we provide a concise and up-to-date discussion on the differential diagnosis and approach of flushing in neuroendocrinology.

Keywords

Flushing Neuroendocrine tumor Carcinoid Pheochromocytoma Histamine Substance P 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ikizoglu G. Red face revisited: flushing. Clin Dermatol. 2014;32:800–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Ray D, Williams G. Pathophysiological causes and clinical significance of flushing. Br J Hosp Med. 1993;50:594–8.PubMedGoogle Scholar
  3. 3.
    Aldrich LB, Moattari AR, Vinik AI. Distinguishing features of idiopathic flushing and carcinoid syndrome. Arch Intern Med. 1988;148:2614–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol. 1998;15(4):253–8.Google Scholar
  5. 5.
    Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc. 2000;21:21–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis, the American Academy of Allergy, Asthma & Immunology, and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45.CrossRefPubMedGoogle Scholar
  7. 7.
    De Filippis EA, Sabet A, Sun MR, Garber JR. Pemberton’s sign: explained nearly 70 years later. J Clin Endocrinol Metab. 2014;99(6):1949–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Jukic T, Kusic Z. Pemberton’s sign in patient with substernal goiter. J Clin Endocrinol Metab. 2010;95(9):4175.CrossRefPubMedGoogle Scholar
  9. 9.
    Schnirer II, Yao JC, Ajani JA. Carcinoid—a comprehensive review. Acta Oncol. 2003;42:672–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg. 1989;26(12):835–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39(6):753–66.Google Scholar
  13. 13.
    Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    O’Toole D, Kianmanesh R, Caplin M. ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Kulke MH, Shah MH, Benson 3rd AB, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.PubMedGoogle Scholar
  16. 16.
    Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendto K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6830 cases. Eur J Cancer Prev. 2003;12:191–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surgical Oncol. 2000;9:173–9.CrossRefGoogle Scholar
  19. 19.
    Koch CA, Azumi N, Furlong MA, Jha RC, Kehoe TE, Trowbridge CH, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999;84(11):4209–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Vinik AI, Gonin J, England BG, Jackson T, McLeod MK, Cho K. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog. J Clin Endocrinol Metab. 1990;70(6):1702–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Balks HJ, Conlon JM, Creutzfeldt W, Stockmann F. Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush. Clin Endocrinol. 1988;29(2):141–51.CrossRefGoogle Scholar
  22. 22.
    Parson HK, Harati H, Cooper D, Vinik AI. Role of prostaglandin D2 and the autonomous nervous system in niacin-induced flushing. J Diabetes. 2013;5(1):59–67.CrossRefPubMedGoogle Scholar
  23. 23.
    Belch JJ, Small M, McKenzie F, Hill PA, Lowe GD, McIntyre DE, et al. DDAVP stimulates prostacyclin production. Thromb Haemost. 1982;47(2):122–3.PubMedGoogle Scholar
  24. 24.
    Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81:41–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62 Suppl 1:33–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60:644–52.CrossRefGoogle Scholar
  27. 27.
    Ruszniewski P, Ish-Shalom S, Wymenga M, O’Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80:244–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18(1):7.CrossRefPubMedGoogle Scholar
  29. 29.
    Woltering EA, Wright AE, Stevens MA, Wang YZ, Boudreaux JP, Mamikunian G, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189–93.CrossRefPubMedGoogle Scholar
  30. 30.
    Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Plouin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard J. Screening for phaeochromocytoma: in which hypertensive patients ? A semiological study of 2585 patients, including 11 with phaeochromocytoma. Nouv Presse Med. 1981;10(11):869–72.PubMedGoogle Scholar
  34. 34.
    Metz SA, Halter JB, Porte Jr D, Robertson RP. Suppression of plasma catecholamines and flushing by clonidine in man. J Clin Endocrinol Metab. 1978;46:83–90.CrossRefPubMedGoogle Scholar
  35. 35.
    McGuinness ME, Talbert RL. Pharmacologic stress testing: experience with dipyridamole, adenosine, and dobutamine. Am J Hosp Pharm. 1994;51:328–46. quiz 404–5.PubMedGoogle Scholar
  36. 36.
    Mouri T, Takahashi K, Sone M, et al. Calcitonin gene-related peptide-like immunoreactivities in pheochromocytomas. Peptides. 1989;10:201–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Herrera MF, Stone E, Deitel M, Asa SL. Pheochromocytoma producing multiple vasoactive peptides. Arch Surg. 1992;127:105–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Smith SL, Slappy AL, Fox TP, Scolapio JS. Pheochromocytoma producing vasoactive intestinal peptide. Mayo Clin Proc. 2002;77:97–100.CrossRefPubMedGoogle Scholar
  39. 39.
    Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Matsuo H, Eto T. Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma. Biochem Biophys Res Commun. 1992;185:134–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Letizia C, Rossi G, Cerci S. Adrenomedullin and endocrine disorders. Panminerva Med. 2003;45:241–51.PubMedGoogle Scholar
  41. 41.
    Nicholls MG, Lainchbury JG, Lewis LK, et al. Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides. 2001;22:1745–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Gläsker S, Neumann HPH, Koch CA, Vortmeyer AO. Von Hippel-Lindau Disease. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2015 Jul 11.Google Scholar
  43. 43.
    Wells Jr SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005;4(1):3–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract. 2004;10(1):5–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004;53:549–53.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36:933–42.CrossRefPubMedGoogle Scholar
  49. 49.
    Miehle K, Tannapfel A, Lamesch P, Borte G, Schenker E, Kluge R, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab. 2004;89(8):3731–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E. Pancreatic neuroendocrine tumor secreting vasoactive intestinal peptide and dopamine with pulmonary emboli: a case report. J Clin Endocrinol Metab. 2016;101(10):3564–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiol. 2016;57(3):260–70.CrossRefPubMedGoogle Scholar
  52. 52.
    Stratakis CA. Diagnosis and clinical genetics of Cushing syndrome in pediatrics. Endocrinol Clin N Am. 2016;45:311–28.CrossRefGoogle Scholar
  53. 53.
    Robyn JA, Koch CA, Montalto J, Yong A, Warne GL, Batch JA. Cushing’s syndrome in childhood and adolescence. J Paediatr Child Health. 1997;33(6):522–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117–23.PubMedGoogle Scholar
  55. 55.
    Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol. 1994;40:479–84.CrossRefGoogle Scholar
  56. 56.
    Afshari A, Ardeshirpour Y, Lodish MB, et al. Facial plethora: modern technology for quantifying an ancient clinical sign and its use in Cushing syndrome. J Clin Endocrinol Metab. 2015;100:3928–33.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    McReynolds SM, Freidberg SR, Guay AT, Lee AK, Pazianos AG, Hussain SF. Hot flushes in men with pituitary adenoma. Surg Neurol. 1995;44:14–7. discussion 7–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Myers BM, Miralles GD, Taylor CA, Gastineau DA, Pisani RJ, Talley NJ. POEMS syndrome with idiopathic flushing mimicking carcinoid syndrome. Am J Med. 1991;90:646–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Niepomniszcze H, Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001;24:628–38.CrossRefPubMedGoogle Scholar
  60. 60.
    Zouboulis CC, Liakou AI. Images in clinical medicine. Flashing, pulsating angioma. N Engl J Med. 2012;366(24):e36.CrossRefPubMedGoogle Scholar
  61. 61.
    Seo I, Bargo PR, Kollias N. Simultaneous assessment of pulsating and total blood in inflammatory skin lesions using functional diffuse reflectance spectroscopy in the visible range. J Biomed Opt. 2010;15(6):060507.CrossRefPubMedGoogle Scholar
  62. 62.
    Sassarini J, Lumsden MA. Vascular function and cardiovascular risk factors in women with severe flushing. Maturitas. 2015;80:379–83.CrossRefPubMedGoogle Scholar
  63. 63.
    Crandall CJ, Manson JE, Hohensee CM, Horvath S, Wactawski-Wende J, LeBlanc, E, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women’s Health Initiative Study. Menopause. Published ahead of print.Google Scholar
  64. 64.
    Krause MS, Nakaijma ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gyncecol Clin N Am. 2015;42:163–79.CrossRefGoogle Scholar
  65. 65.
    Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  1. 1.Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institutes of Health (NIH)BethesdaUSA
  2. 2.Division of EndocrinologyUniversity of Mississippi Medical CenterJacksonUSA
  3. 3.G.V. (Sonny) Montgomery VA Medical CenterJacksonUSA

Personalised recommendations